PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

		tute for form 1449A	o persons are required to respond to a collect VPTO			
					Com	plete if Known
			TION DISCLOSURE NT BY APPLICANT	Application	Number	09/269,903
0	י אי	(use as mar	ny sheets as necessary)	Fill - Doto		M. C 4000
	•	اء َ		Filing Date First Named	Inventor	May 6, 1999 Peter James Watts
NOV 2	2 1990	0		Group Art U		1645 /6/6
	.000	6		Examiner Na		
<b>S</b> neet	·	IS OF I	4		cket Number	WC 131
	210	<del>(</del>		rationity Do	onor realizor	WO 101
MADE	MYKK		U.S. PA	TENT DOCUME	NTS	
Examiner Initials*	Cite No.1	US Patent Docum	nent Name of Patentee or of Cited Docum		Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind (if k	Code <sup>2</sup> (nown)			
24/11	,	4,663,308	Saffran, et al.		05-05-1987	
PVI		4,871,549	Ueda, et al.		10-03-1989	
PIZZ		4,945,080	Lindstrom, et al.		07-31-1990	
DV.Y.		4,963,573	Freyne, et al.		10-16-1990	
OVS		5,310,558	Pozzi, et al.		05-10-1994	
01.71		5,514,663	Mandel		05-07-1996	
012/		5,631,022	Mandel, et al.		05-20-1997	
01/9/		5,651,983	Kelm, et al.		07-29-1997	
DIKK		5,656,290	Kelm, et al.		09-12-1997	
CALL.		5,686,106	Kelm, et al.		11-11-1997	
					ļ	
		,				
		ļ — — — — — — — — — — — — — — — — — — —			<del> </del>	
				<u> </u>		
				· · · ·		
		1		<del></del>		
		<del> </del>			<del> </del>	
		<del> </del>			<del>  </del>	
		<del>                                     </del>				
		†		· <del>· · · · · · · · · · · · · · · · · · </del>	<del>                                     </del>	
		†			1	
		1			<del>                                     </del>	
		<u> </u>				· · · · · · · · · · · · · · · · · · ·
Examine		A In	1/9/10		Date Considered	1 1 18
Signature		TOURSE	· William			10 January 2000

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

	1	
•	Т	

	Substit	ute for t	orm 144	PAPIO				Complete	if Known		
					DISCLOSU APPLICA		Application Numb	per	09/269,903		
		1	ice ac m	any cheets	as necessary)		<b>'</b>				
011	P 🔊	' '	13C 63 111	arry street	do necessary)		Filing Date	<del> </del>	May 6, 1999		
•		$\sim$					First Named Inver	Peter James Watts			
100 0 1	1000	<u>21                                    </u>					Group Art Unit		1615 /6/6		
NOV 2 7	( 1333	6				•	Examiner Name	<del></del>	Pernali V. Williams		
eet	1 2	250	of		4		Attorney Docket N	lumber	WC 131		
		KK.									
& TRAD	MARK						TENT DOCUMENT				
caminel nitials*	No.1	Office.3		Patent Doo	Kind Code	Name of Paten Applicant of Cited I		Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Onice.	'	vumber	(if known)					ı	
0 1		DE	42-36-	025	A1	Merck Pate	nt GmbH	04-28-1-994		丰	
12		GB	2 166	051	Α	Alza Corp.		04-30-1986		Ť	
1/	,	GB	2 174	599	Α	Norwich Ea Pharmaceut		11-12-1986		Ť	
		GB .	2 238	243	A	National Re Developmer		05-29-1991		T	
1.77		EP	0 221	601	A1	Janssen Ph	armaceutica N.V.	05-13-1987		Ť	
0.10		EP	0-338-	383-	A2	Schwarz-Ph	arma-AG	10-25-1989		于	
14	·	EP	0 365	947	A1	Pharmacia /	AΒ	05-02-1990		T	
VI		EP	0 513		B1	Danbiosyst		10-20-1993		$\perp$	
	,	EP	0.519	8.70	A1	Präparate	harmazeutische	12-23-1992		$\pm$	
1/1/		EP	0 572		A2		a Chimica S.p.A.	12-08-1993		ᆚ	
11/		EP	0 621		A1	Ciba-Geigy		10-26-1994	· · · · · · · · · · · · · · · · · · ·	┸	
24		EP	0 640		A2			03-01-1995		┵	
V.R.	,	EP	0 673		A2	<u> </u>	n-La Roche AG	09-27-1995		↓	
M		wo	89/112		A1	Agricultural Research C	ouncil	11-30-1989			
		wo-	90/132		A1	Kaisha	aku-Kabushiki	11-15-1990		1	
GA!		wo	91/168	381	A1	Developmer Hebrew Uni Jerusalem	nt Company of the iversity of	11-14-1991			
201		wo	92/014	57	A1	Rhodes, et	al.	02-06-1992		Ι	
Vila)		wo	92/144		A1	Rhodes, et		09-03-1992		Ι	
ン!		wo	95/064		A1	Galenik Lab	or Freiburg GMBH			$\Gamma$	
242		wo	95/140		A1	lbah, Inc.		05-26-1995		$\perp$	
2/4/		wo	95/351		A1	Danbiosyst		12-28-1995		$\perp$	
PHIL		wo	96/300	16	A2	Janssen Ph	armaceutica N.V.	10-03-1996		L	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

flease type a plus sign (+) inside this box →	+	
flease type a plus sign (+) inside this box →		i

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	นอรแน	ute for form 1449A/P		d	complete if Known		
	ST.	ATEMENT BY	DISCLOSURE APPLICANT	Application Number	09/269,903		
011	3 E	use as many sheet	s as necessary)	Filing Date	May 6, 1999		
	-	<u>~</u> ]		First Named Inventor	Peter James Watts		
NOV 2 2	1999	21		Group Art Unit			
2 2	.000	o)		Examiner Name	19/15 /6/6		
neet	- 3	of I	4	Attorney Docket Number	Pernell V. Williams WC 131		
	<del></del> ~		<del>"</del>	Attorney Docket Humber	10 131		
MADE	MADY.		OTHER ART	NON PATENT LITERATURE DOCUM	MENTS		
caminer's	Cite			(in CAPITAL LETTERS), title of the article			
Initials*	No.1			al, serial, symposium, catalog, etc.), date, p			
				publisher, city and/or country where publis			
14/41		ASHFORD, et al., "	In Vivo Assessment	of Colonic Drug Delivery Systems,"	Br. Pharm. Conference Abstract 13, p.		
1//		1049 (1992).					
لممد							
				of liquid-filled Capill ® potato starch	capsules with biphasic release		
11/2		characteristics," In:	. <i>J. Pharm.</i> 134:223	-30 (1996).			
		,					
MIK			•	Release" in <u>Drug Delivery to the Garage</u>	astrointestinal Tract (Hardy, et al., eds.)		
<i> .//</i> .		Ellis Horwood:Chick	nester, 1989.				
nita .		VEADVOAL					
				the in vivo behaviour of enteric coa	ted starch capsules," Int. J. Pharm.		
. //	.	112:207-13 (1994	).				
ala K	<del>'</del>	VODE EV at al. "D	-1	sitio dura delironi II I Control Del	10-121 20 (1002)		
1.1/		KOPE EK, et al., P	olymers for colon-spe	ecific drug delivery," J. Control. Rel	. 19:121-30 (1992).		
١ ' ا	1						
a a l		MILO IEVIC et al	#In Missa and In Missa		ts for colon specific drug delivery,"		
				evaluation of arrylose coated pelie	is for colon specific drug delivery,		
/ · / ·		rioceed. intern. 3y.	inp. Control. Nel. Bloc	act. Mater. 20.200-05 (1993).			
11/11	-	RURINSTEIN & GUI	CO-KARIR *Synthagis	and swelling dependent enzymatic	degradation of borax-modified guar gum		
/////				earma Sciences 5:41-46 (1995).	degradation of borax-modified guar guin		
7.4.		ioi cololilo delively	purposes, 0.7.7.77	anna coloneca o.41 40 (1000).			
12.11		RUBINSTEIN et al	"Colonic Drug Delive	ery: Enhanced Release of Indometh	acin from Cross-Linked Chondroitin Matrix		
			nt," Pharm. Res. 9(2):		zom mom oroso zimioa onomarokim matrix		
^			, , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	.2,0,0,002,.			
n Ill 1		RUBINSTEIN et al.	"In Vitro Evaluation	of Calcium Pectinate: A Potential C	Colon-Specific Drug Delivery Carrier,"		
1/1/		Pharm. Res. 10(2):			reserve of the princip carrier,		
~ ~ ~ \	- 1		,				
nd		SIEFKE et al "Col	on Targeting with 8-0	D Matrix Films " Fur 1 Pharm Rie	onharm 40 (suppl ):335 (1994)		
VA)		SIEFKE, et al., "Col	on Targeting with β-0	CD Matrix Films," Eur. J. Pharm. Bio	opharm. 40 (suppl.):33S (1994).		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Please type a				·		Approved for use through 10/31/99. Patent and Trademark Office: U.S. DEPARTMENT	O/SB/08A (10-9 OMB 0651-003 OF COMMERCE			
			Act of 1995, no orm 1449A		o a collection of information unless it contains	a valid OMB control number				
	Caboa					Complete if Known				
		ATE	MENT	N DISCLOSURE BY APPLICANT	Application Number	09/269,903	<del></del>			
	,	Meg a	s many sh	neets as necessary)						
NOV	2 0	۱., `			Filing Date	May 6, 1999				
PATE	< 2 1g	0 09			First Named Inventor	Peter James Watts				
煙.		~ 5/			Group Art Unit Examiner Name	700				
SAFOL		4.50	of I	4	Attorney Docket Number	Pernell 1/2 Will;	ans			
SINGAN I	MARK	100	01	4	Attorney bocket Number	110 131				
	MIHIT			OTHER ART - N	NON PATENT LITERATURE DOC	CUMENTS				
Examiner's Initials*	Cite No.1	VAN D	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published  THE UNITED STATES PHARMACOPOEIA, USP23, pp. 1791-93 (1994).  VAN DEN MOOTER, "Azo polymers for colon-specific drug delivery," Int. J. Pharm. 87:37-46 (1992).  WILDING, et al., "Gastrointestinal Transit and Systemic Absorption of Captopril from a Pulsed-Release Formulation,"							
				):654-57 (1992).						
	-	_					·			
						,				
					<del></del>					
I .		1								

Signature	Jevell	2	Willia	Date Considered	10	January	2000	

Inda Canaidanad

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

982229v l

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.